Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel

Last updated: August 5, 2011
Sponsor: University Hospital Tuebingen
Overall Status: Completed

Phase

2/3

Condition

Vascular Diseases

Claudication

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT00163267
mi-1
D.3100340
  • Ages 18-90
  • All Genders

Study Summary

The Mirror Study is a randomized, double-blinded mono-centre trial the access the periinterventinal and postinterventional administration of clopidogrel in patients with peripheral vascular disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Peripheral arterial disease which requires intervention

Exclusion

Exclusion Criteria:

  • Patient already on coumadin or clopidogrel

  • Acute onset of PVD symptoms

  • Patient requiring an operation

  • Contraindication to aspirin and clopidogrel

Study Design

Total Participants: 80
Study Start date:
September 01, 2005
Estimated Completion Date:
April 30, 2011

Study Description

Clopidogrel is approved for secondary prevention of atherosclerosis in patients with peripheral vascular disease. Currently there are no data about the amount of platelet activation during peripheral arterial intervention, the effect of clopidogrel on platelet adhesion and its clinical impact.

Patients with chronic peripheral arterial disease receive placebo or clopidogrel before the intervention and for 6 months in follow-up. Platelet activation, the effect on macro-and microcirculation will be assessed as well as clinical endpoints.

Connect with a study center

  • University Hospital of Tuebingen

    Tuebingen, 72076
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.